Wegovy and Zepbound — two of three GLP-1 medications currently approved for weight loss in the U.S. — have monthly list prices of $1,349 and $1,060, respectively. And, the medication needs to ...

Dive Brief: Cigna is building on client demand for tools to support patients on GLP-1 weight loss drugs, announcing two new programs on Friday meant to improve clinical care around the dispensing ...

aprott/iStock via Getty Images. Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the obesity drug class popularized by Novo ...

Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the obesity drug class popularized by Novo Nordisk (NVO) and Eli Lilly (NYSE ...

In response to Novo Nordisk claims that PBMs contribute to high drug prices, representatives from Cigna Group/Express Scripts, CVS Health/Caremark and UnitedHealth Group/OptumRx told Mr. Sanders a ...

Adding 5m GLP-1 patients at slightly lower prices or 21m at LLY price levels both lead to 20%+ upside in the stock. Both diabetes and obesity are blue ocean markets, composed of low GLP-1 usage.

GLP-1 agonists and related drugs have been getting the most attention, because they are so popular and so expensive, but GLP-1 cost panic is a symptom of the fact that the median annual price for ...

In the letter to Sanders, Novo also argued that the Senator’s complaints fail to account for the time, manpower and more than $10 billion Novo invested in the development of its GLP-1 medicines ...

Cigna is moving to limit how much health insurance providers and employers have to pay for pricey and in-demand obesity medications. The insurer plans to cap annual price increases for the drugs ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers manage GLP-1 utilization. Cigna also posted first quarter results well ...

Cigna has announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the obesity drug class popularized by Novo Nordisk and Eli Lilly becomes a key component of ...